Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

NCT03576443 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

NETWORK

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Idelalisib

Sponsor

Nordic Lymphoma Group